Chapter 100: Drug Therapy for Sexually Transmitted Infections

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

So back in the 1930s, we could actually cure gonorrhea with just like basic sulfonamides.

Right, which sounds wild now.

I know, right?

It was an easy fix.

But today,

this shape -shifting bacteria has outsmarted almost every single drug we've thrown at it.

Yeah, it really has.

Leaving us heavily reliant on, you know, a single last resort injection.

So welcome to the deep dive.

Thanks for having me.

If you're a college nursing student listening to this right now, maybe prepping for a pharmacology exam or getting ready to step onto the clinical floor, consider this your ultimate study guide.

Absolutely.

Because today, we are opening up this pharmacology for nursing care, the 12th edition, specifically chapter 100.

And our mission here is to translate all this incredibly dense high stakes information into clear, actionable knowledge.

And we really need to emphasize the stakes here.

I mean, the CDC data highlighted in this chapter, it shows an escalating war between bacteria and medicine.

Yeah, the numbers are honestly terrifying.

They are.

Over half of all new sexually transmitted infections are occurring in people aged 15 to 24.

Which is exactly the patient population you'll be seeing so much of in practice.

Right.

And despite the physical isolation of the COVID -19 pandemic, where, you know, logic kind of dictates transmission would plummet, infection rates actually continue to rise.

That makes no sense.

It's a massive public health challenge.

And the pharmacology we're about to discuss really reflects the extreme urgency of that challenge.

OK, so let's unpack this because right at the beginning of chapter 100, the text points out this unique structural hurdle for students.

Yeah, the formatting shift.

Right.

Usually you learn pharmacology by drug classes.

You know, you learn what a macrolide does and then you just apply it.

But the 2021 CDC guidelines for STIs, they use generic drug names categorized by the specific infecting organism.

Which can be super frustrating for students, I know.

But it forces you to think like a clinician rather than a chemist.

Oh, that's a good way to look at it.

Yeah.

You can't just memorize drug families here.

You have to understand the specific pathogen, where it lives in the body, and how a specific molecule disrupts it.

So we're basically tracking the bugs.

Exactly.

We're going to build that understanding today by looking at the heaviest hitters first, you know, the silent spreaders and the adaptive shapeshifters.

And then we'll move into how to treat complex infections when you don't even know exactly which bug you're fighting.

Perfect.

Let's start with the ultimate silent spreader, Chlamydia trecomatis.

The big one.

Yeah.

The preliminary 2021 CDC data in the text shows over 1 .6 million cases.

That makes it the most frequently reported bacterial STI.

But the terrifying part is the clinical presentation or, you know, the total lack of it.

That is the primary clinical reality of Chlamydia.

It's an intracellular organism that frequently causes absolutely no symptoms.

Especially early on, right?

Especially in the early stages.

Patients simply do not know they're infected.

But while it is silent, it is definitely not harmless.

Because of what it does long term.

Exactly.

If we look at the pathophysiology, untreated Chlamydia ascends into the reproductive tract.

The CDC estimates that 10 to 15 percent of women with untreated chlamydial infections will develop pelvic inflammatory disease.

And PID isn't just like a painful infection.

The inflammation physically scars the delicate lining of the fallopian tubes.

It's permanent damage.

Right.

And that scarring can block a fertilized egg from reaching the uterus, which leads directly to ectopic pregnancy or even complete infertility.

Which is exactly why the CDC recommends annual screening for all sexually active women 24 years of age and younger.

As well as, you know, older women with risk factors.

And importantly, the text notes this screening recommendation explicitly includes transgender men and gender diverse patients who have a cervix.

Yes.

Very important point for inclusive nursing care.

So when a screening comes back positive, we turn to box 100 .2 in the text for treatment.

For uncomplicated urethral, cervical or rectal infections in adults and adolescents, the gold standard is doxycycline.

Right.

100 milligrams by mouth every 12 hours for seven days.

And if they can't take that, azithromycin or levofloxacin are the alternatives.

Yeah.

But here's my question.

If doxycycline is the absolute first choice, what do we do for a pregnant patient?

Oh, you have to pivot immediately.

Right.

Because I know tetracyclines are a major red flag in obstetrics.

But what is the actual mechanism?

Like isn't giving doxycycline during pregnancy,

like trying to build a house with toxic materials, what is it actually doing to the fetus?

That's a great analogy.

It really comes down to chemical affinity.

Doxycycline is a strong chelating agent.

Meaning it binds to things.

Exactly.

It aggressively binds to calcium.

So when a pregnant patient takes it, the drug crosses the placenta and literally hunts down areas of rapid calcification.

Oh, wow.

So the baby's bones.

Yes.

The developing fetal bones and the tooth buds.

It deposits right there, causing permanent discoloration of the teeth and skeletal deformities.

That is awful.

Which is exactly why it is strictly contraindicated in the second and third trimesters.

Okay.

That makes total sense.

It's not just universally toxic.

It's chemically targeting the baby's structural development.

Precisely.

So looking at box 100 .3, the text pivots for pregnant patients.

This reminds me it becomes the preferred treatment, usually given as just a single one gram oral dose.

Right.

And we also have to consider the risk to the neonate if the pregnant patient goes untreated.

Because they can catch it during delivery.

Exactly.

About half of infants born to patients with active cervical chlamydia will acquire the infection as they pass through the birth canal.

Wow.

Half.

Yeah.

It exposes them to chlamydial pneumonia and ophthalmia neonatorum, which is this really severe conjunctivitis.

And the treatment for those infants isn't doxycycline or azithromycin.

The text specifies oral erythromycin base or erythromycin ethyl succinate.

Correct.

But there's one more lifespan nuance we have to cover before we move on.

And it's a heavy one.

Predolescent children.

Yeah, this is a very sensitive but critical nursing topic.

If a child over two years old is diagnosed with chlamydia, the text states that sexual abuse is the most likely cause.

Right.

Because of the severe legal and protective implications of that diagnosis, a standard rapid test is just not enough.

You need something totally concrete.

You must use a nucleic acid amplification test.

It's highly sensitive and specific, ensuring there is absolute definitive proof of the pathogen's DNA.

OK, let's transition to the other bacterial heavyweight, which is gonorrhea, caused by niseria gonorrhea.

The shapeshifter.

Right.

Now, unlike chlamydia, if a patient has a penis, gonorrhea usually announces itself loudly.

I mean, intense burning during urination and a purulent pus -like discharge.

It's very hard to ignore.

But in a patient with a vagina and cervix, it often mimics chlamydia by remaining entirely asymptomatic.

And that asymptomatic presentation, again, leads to silent spread and sterility.

But gonorrhea also carries a severe systemic threat.

Beyond the reproductive tract.

Yes.

If it enters the bloodstream, which is bacteremia, it can cause disseminated gonococcal infection or DGI.

Oh, that sounds bad.

It is.

The bacteria settle into distant tissues, causing patechial skin lesions, arthritis, and tenosynovitis.

Which is inflammation of the tendon sheaths, right?

OK, but here's where the pharmacology gets really interesting.

I mentioned the timeline in the intro, and the text outlines this evolutionary arms race perfectly.

It's fascinating.

In the 30s, sulfonamides worked.

By the 40s, they completely failed.

Then penicillin worked until around 1976.

Then fluoroquinolones worked until 2007.

Then cephalosporin.

It's just kept adapting.

Right.

By 2012, the CDC recommended dual therapy, two antibiotics at once, just to keep the bacteria cornered.

But the 2021 guidelines in this textbook have flipped the script again.

What's fascinating here is that they have returned to monotherapy.

And you have to understand the biological reasoning behind this shift.

Right, because intuitively,

less drugs sounds worse for a superbug.

It does, but it's all about antimicrobial stewardship.

When you give a patient two powerful antibiotics, you aren't just killing the gonorrhea.

You're carpet bombing the patient's entire microbiome.

Oh, so all the good bacteria, too.

Exactly.

You wipe out the beneficial bacteria in the gut and vagina, which can lead to opportunistic super infections.

So to protect the microbiome, the CDC scaled back to a single drug.

But it's highly specific.

To treat uncomplicated gonorrhea in adults, the standard is a single 500 -milligram dose of ceftriaxone.

Yes.

And there's a weight parameter to memorize here for the exams.

If the patient is 150 kilograms or more, that dose jumps to one gram.

But crucially, the route is IM intramuscular.

Right.

Why a shot instead of a pill?

Pharmacokinetics.

An intramuscular injection creates a depo effect.

Meaning it stays in the muscle.

Right.

Meaning the drug is absorbed slowly and maintains a high sustained bactericidal concentration in the blood.

Plus, a shot guarantees 100 % patient compliance.

So true.

You don't have to worry about them missing a dose at home.

Exactly.

You watch them take it.

Now, the text also flags pharyngeal gonorrhea as a major issue.

Yes.

That's a silent reservoir.

It's harder to eradicate, right?

So if a patient has gonorrhea elsewhere and engages in oral sex, you must routinely swab the pharynx.

Always.

And what about infants born to mothers with gonorrhea?

Neonatal gonococcal ophthalmia is much more aggressive than the chlamydial version.

It can rapidly penetrate the intact cornea and cause permanent blindness.

Oh my god.

Because the stakes are so high, state laws require immediate postpartum prophylaxis for all infants,

regardless of maternal testing.

Just across the board.

Box 100 .6 outlines the standard, a 20 .5 % erythromycin ophthalmic ointment instilled directly into both eyes.

Moving on to our third major pathogen.

We face a disease that acts like, kind of like a biological time bomb, syphilis.

Caused by the spirit shade treponema pallidum.

Right.

And the text highlights a really devastating trend.

A 235 % increase in congenital syphilis from 2016 to 2021.

This huge spike.

To understand how to treat it, we have to understand its three distinct stages, right?

Yes.

Primary syphilis occurs one to four weeks after infection.

It presents as a chancre.

Which is?

A hard red, painless ulcer at the entry site.

But the trick here is that the chancre heals completely on its own, which gives the patient this false sense of security.

Like they're cured.

Right.

But the bacteria hasn't died, it has just moved deeper.

Right into the bloodstream.

And that triggers secondary syphilis a few weeks later.

The patient gets flu -like symptoms, swollen lymph nodes, and skin lesions.

Often on the palms of the hands and soles of the feet.

Yes.

That palm and sole rash is a classic sign.

But then, those symptoms resolve too.

Leading to the latent phase, which can actually last for years.

Just hiding out.

Hiding in the body.

Finally, in about a third of untreated patients, tertiary syphilis erupts five to forty years later.

Decades later.

Decades.

By this point, the spirachet has infiltrated deep tissues, causing severe damage to the heart valves and neurosyphilis.

Which manifests as senility, paralysis, and severe psychiatric deterioration.

So we have an organism that hides for decades.

What is the pharmacological weapon of choice here?

Penicillin G.

It is the undisputed drug of choice for all stages of syphilis.

Okay, so just penicillin G across the board.

Well the critical nursing knowledge lies in box 100 .7.

You must choose the correct formulation based on where the bacteria is hiding.

For primary, secondary, and early latent syphilis, you use benzathine penicillin G given intramuscularly.

It absorbs very slowly, providing a low but persistent level of penicillin for weeks to clear the spirachettes from the tissues.

But for neurosyphilis, the bacteria is hiding in the brain.

Benzathine penicillin G won't work for that, right?

Exactly why formulation matters.

To treat neurosyphilis, the drug must cross the blood -brain barrier.

Which is hard to do.

Very hard.

So you have to use aqueous crystalline penicillin G given intravenously.

It is highly water soluble and reaches high enough peak concentrations in the blood to actually push through the tight junctions of the blood -brain barrier and bathe the central nervous system.

Okay, let me throw a clinical wrench into this.

Go for it.

What if a patient has syphilis but their chart says they are allergic to penicillin?

We established earlier that doxycycline is a powerful antibiotic.

Can we just grab a backup drug like doxycycline?

This raises an important question and it's a scenario where the clinical guidelines are incredibly rigid.

If the patient is a non -pregnant adult with early syphilis, yes, you can use doxycycline or tetracycline as an alternative.

But if the patient is pregnant, or if they have neurosyphilis, the CDC mandates that they must receive penicillin.

Wait, even with a documented allergy?

Why risk anaphylaxis when we have other drugs?

Because no other drug has been definitively proven to cure neurosyphilis or consistently prevent the transmission of syphilis to the fetus.

The risk of congenital syphilis or progressive brain damage outweighs the logistical hurdle of the allergy.

So what do you do as the nurse?

The nursing implication is strict.

You first verify the allergy with a skin test.

If it is a true allergy, the patient must be admitted for a strict penicillin desensitization protocol.

In the hospital?

In an ICU setting.

You give them microscopic, gradually increasing doses of penicillin to exhaust their mast cells so they can safely tolerate the full therapeutic dose.

That is a phenomenal conceptual point for nursing exams.

It's not just about knowing the drug, it's about knowing when the standard alternative is unacceptable.

Let's shift away from these systemic invaders and talk about localized ecological disasters.

Bacterial vaginosis and trichomoniasis.

Bacterial vaginosis, or BV, requires a shift in how we think about infections.

It's not caused by a single external bug invading the body.

It is a syndrome caused by an alteration in the normal vaginal microflora.

Normally, lactobacilli produce hydrogen peroxide and keep the vaginal pH acidic, which suppresses other bacteria.

But in BV, the lactobacilli die off.

And the pH rises.

Right, it rises above 4 .5.

And organisms like Gardnerella vaginalis and various anaerobes aggressively overgrow.

This leads to a thin discharge, a distinct fishy odor, and the presence of microscopic clue cells.

To understand clue cells, imagine a normal epithelial cell from the vaginal lining.

In BV, the overgrown bacteria physically cling to the outside of that cell in such massive numbers that they completely obscure the cell's borders.

Like a donut rolled in powdered sugar.

That's a perfect visual when you see that under a microscope you have your diagnosis.

For treatment, Box 100 .9 outlines the regimens oral or vaginal metronidazole, or vaginal clindamycin cream.

But we have to talk about pregnancy again.

Always a consideration.

The text explicitly warns against certain formulations here.

It is a critical safety alert.

Drugs like secnidazole and tinnidazole are not recommended in pregnancy due to adverse effects seen in animal reproduction studies.

So stay away from those.

Right.

Furthermore, even preferred drugs have formulation restrictions.

Clandes, 2 % vaginal cream, and metronidazole, 1 .3 % vaginal gel,

are not recommended during pregnancy simply because we lack sufficient safety data for those specific topical delivery systems.

Now what about trichomoniasis?

This is the most common non -viral STI in the U .S.

Caused by the protozoan Trichomonas vaginalis.

Right.

And in a patient with a penis, it's usually completely silent.

But in a patient with a vagina, it causes a frothy, malodorous, yellow -green discharge.

Because it is a protozoan, the treatment is highly specific.

A single oral dose of either metronidazole or tinnidazole.

Which disrupts their DNA, right?

Yes.

These drugs disrupt the DNA structure of the protozoa.

However, the biggest hurdle here is not the drug's efficacy.

It is the ping -pong effect of reinfection.

Ah, right.

Treating a patient for trichomoniasis, but not treating their asymptomatic partner, is like mopping a floor while the sink is still overflowing.

Exactly.

They're just going to get infected again.

You're doing the work, but the environment is still compromised.

You have to treat all sexual partners simultaneously to actually clear the infection.

It's a vital nursing implication.

And regarding tinnidazole, there is a specific maternal alert.

It is absolutely contraindicated in pregnancy and breastfeeding.

So no exceptions.

Well, if a breastfeeding patient absolutely must take tinnidazole, they have to pump and discard their breast milk during the treatment.

And for a full 72 hours after the final dose to ensure the infant is not exposed.

OK, let's move on to the only viral STI detail in Chapter 100,

genital herpes.

We were dealing primarily with HSV2 and increasingly HSV1, affecting over 50 million people in the US.

It's incredibly common.

The primary infection can be brutal, two painful vesicles that rupture into ulcers, accompanied by fever and swollen lymph nodes.

But the most vital biological concept for a student to grasp here is latency.

Yes, the visible sores eventually heal, usually in a few weeks.

But the virus doesn't die.

No, it retreats, right?

The virus travels retrograde backward up the sensory nerves and establishes a permanent dormant residence in the dorsal root ganglion.

Just hiding again?

It hides there, completely shielded from the immune system.

Because it is dormant and not actively replicating, our antiviral drugs cannot target it.

So there's no cure?

There is no cure.

The virus will periodically reactivate, travel back down the nerve, and cause recurrent outbreaks for the rest of the patient's life.

So if there's no cure, what are we actually achieving with medication?

Like, what are the drugs in box 100 .11 actually doing?

Why take acyclovir, famsclova, or valacyclovir?

These drugs are DNA polymerase inhibitors.

When the virus reactivates and tries to multiply, these drugs insert themselves into the viral DNA chain and terminate it.

Oh, I see.

This achieves two things.

It blunts the physical pain of the outrock, and it significantly shortens the period of viral shedding, meaning the patient is contagious for a shorter amount of time.

So what does this all mean for transmission?

The text makes a massive distinction regarding valacyclovir here.

It does.

Valsyclovir is unique.

It's the only drug in this class formally shown to actively reduce the transmission of genital herpes to a susceptible partner.

By how much?

It cuts the risk by about 50 % when taken daily as suppressive therapy.

But 50 % is a coin flip.

It's not 100%.

Exactly.

Which means your patient teaching must be brutally honest.

Medication alone is not a shield.

Barrier methods are always required.

And what about during an active breakout?

Because the viral load on the skin spikes massively during an outbreak, patients must abstain from sexual contact entirely when active lesions are present.

There is also a major maternity protocol here.

Neonatal herpes can cause permanent blindness, severe neurologic damage, or fatal disseminated infection.

The neonate's immune system is naive, so exposure during delivery is catastrophic.

So how do we prevent that?

If a pregnant patient has active herpes lesions, or even prodromal symptoms at the onset of labor, a cesarean section is absolutely required to bypass the infected birth canal.

Period.

It is a non -negotiable intervention.

All right, we are entering the final stretch.

The last section of chapter 100 shifts focus.

Instead of targeting specific bugs, we are looking at specific anatomical syndromes where the exact organism might be unknown initially.

The first is NGU, or non -gonococcal urethritis.

This is inflammation of the urethra caused by anything other than gonorrhea.

So mostly chermedia trecomatus, right?

Right.

Particularly in sexually active adolescent girls.

Because you cannot wait for lab cultures to return to provide relief, you utilize presumptive treatment.

Which means treating based on the most likely cause.

Doxycycline is the primary choice, shifting to azithromycin if the patient is pregnant.

Next is a condition we explored earlier, pelvic inflammatory disease, endometritis, pelvic peritonitis, and tubo ovarian abscesses.

The dangerous one.

Yeah, the good news is cases have dropped roughly 40 % recently due to better screening and education.

But when it happens, the pharmacology is incredibly aggressive.

It has to be, because PID is a polymicrobial infection.

It is not just chlamydia or gonorrhea.

It's a mix.

It involves mycoplasma and a host of anaerobic bacteria that thrive in deep tissue abscesses.

No single antibiotic can handle that kind of diversity.

Since multiple organisms are involved, you can't just send in a single officer.

You need a whole SWAT team of antibiotics.

That is a highly accurate way to visualize it.

You need ceftriaxone to break the aerobic locks, the gonorrhea.

But that won't get you past the anaerobic booby traps deep inside the abscesses.

Right, for that you need a drug like metronidazole.

And you need doxycycline for the atypical organisms.

For hospitalized inpatients, box 100 .13 details regimens like IV ceftriaxone combined with doxycycline and metronidazole.

You hit the infection from every pharmacological angle simultaneously.

And for outpatients.

Box 100 .14 outlines the outpatient approach.

A single IM injection of ceftriaxone followed by 14 days of oral doxycycline and oral metronidazole.

But there is a critical nursing parameter tied to this, isn't there?

The 72 -hour rule.

Yes.

Because the risk of fallopian scarring and permanent sterility is so high, outpatients must be clinically reevaluated within 72 hours.

To see if the SWAT team is working.

Exactly.

If their pain and inflammation are not demonstrably improving on the oral regimen, the vault isn't opening.

They must be admitted to the hospital and stepped up to IV therapy.

The final two syndromes are acute epididymitis and proctitis.

Let's start with epididymitis, which presents a severe pain in the back of the testicle with a fever.

The baseline treatment is our standard duo -ceftriaxone and doxycycline.

However, box 100 .15 introduces a vital clinical exception.

If the patient's history includes insertive anal sex, the infection might not be an STI at all.

Wait, really?

What else could it be?

It could be caused by enteric or intestinal organisms like E.

coli.

Oh, that makes sense.

In that scenario, you must add levofloxacin to the regimen to ensure you have coverage against those specific gut bacteria.

Plus, nursing care includes bedrest, ice packs, and analgesics.

And finally, proctitis.

This is inflammation of the rectum usually resulting from receptive anal intercourse.

Standard treatment is ceftriaxone plus doxycycline.

But box 100 .16 flags a massive exception here, too.

Right.

If the patient presents with bloody anal discharge, tenesmus, which is the painful, constant urge to defecate or a positive rectal chlamydia test, a standard seven -day course of doxycycline will fail.

Why?

The tissue penetration requires more time, so you must extend the doxycycline to a full 21 days.

And if you observe perianal ulcers, you must empirically add antiviral treatment for HSV.

OK, take a deep breath.

We just navigated a massive maze of pharmacology.

We did.

But if we synthesize it, clear themes emerge.

Notice the heavy reliance on doxycycline and ceftriaxone.

They are the absolute workhorses of chapter 100.

Yeah, they show up everywhere.

And notice how pregnancy fundamentally alters your drug choices.

Drugs that bind to fetal calcium or lack safety data force you to pivot to azithromycin or utilize complex penicillin desensitization.

Which is such a critical concept for exams.

And underlying everything is the principle of antimicrobial stewardship, which dictates exactly why we use these specific drugs in these exact combinations.

And speaking of stewardship, I want to leave you with a provocative thought to chew on.

We watched the history of gonorrhea outsmarting sulfonamides, penicillin, and fluoroquinolones.

It's relentless.

Right now, ceftriaxone is standing alone as our preferred monotherapy defense.

As a future nurse, you have to wonder what happens to our protocols when the gonococcus eventually learns to outsmart that too.

Ceri thought.

Will the future of STI treatment even rely on reactionary antibiotics?

Or will we have to shift to prophylactic strategies, like taking doxycycline before or immediately after an exposure?

And if we do that on a mass scale, what new evolutionary monsters might we accidentally create?

It's the ultimate pharmacological chess game.

It is a question that will undoubtedly define the next decade of infectious disease protocols.

You'll be the nurses on the front lines managing it.

Thank you for joining us for this deep dive.

Good luck in your exams and good luck in clinical practice.

From everyone here at the Last Minute Lecture Team,

you've got this.